Interchangeable Biosimilars: Key Points for Patients


Jonathan Kay picture

Jonathan Kay, MD
UMass Memorial Health
Worcester, MA

Jonathan Kay, MD, defines biosimilarity and the necessary requirements for that designation and discusses the implications of interchangeability on patient access to biological products.

©2022 Boehringer Ingelheim Inc. All Rights Reserved. SC-US-74798 11/22